Allozymes raised $15M in a series A to grow its business and expand its enzyme-tailoring services.
Amount Raised
$15 Million
Round Type
Series A
SingaporeBiotechnologyDescription
Allozymes has raised a $15 million series A funding round to expand its business and accelerate the screening of enzyme variants, aiming to reach 20 million variants per day. The company plans to offer more from-scratch work and expand its enzyme-tailoring services to fulfill a wider range of needs.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Allozymes that raised within 45 days of this round, from Fundz verified event records.
- Immunis raised $20M on June 17, 2024.
- Primrose Bio raised $15M on June 17, 2024.
- Elion Therapeutics raised $81M (Series B) on June 17, 2024.
- Insightec raised $150M on June 17, 2024.
- Naveris raised $17M on June 17, 2024.
- Maximum Fidelity Surgical Simulations raised $2.2M (Seed) on June 17, 2024.
Who to call at Allozymes, and when
A new round usually means Allozymes is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Allozymes raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Allozymes, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Allozymes. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Allozymes raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAllozymes raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.